{"title":"Targeting B Cells for the Treatment of Idiopathic Inflammatory Myopathy.","authors":"Tao Liu, Bo Chen, Geng Yin, Qibing Xie","doi":"10.1007/s12016-025-09047-0","DOIUrl":null,"url":null,"abstract":"<p><p>Idiopathic inflammatory myopathy (IIM) is a group of heterogeneous diseases that can affect multiple systems. Currently, it is classified into different subtypes based on myositis-specific antibodies and muscle tissue pathology. These subtypes vary in treatment response and clinical prognosis, with poor treatment outcomes observed in cases of rapidly progressive interstitial lung disease and severe muscle involvement. Despite conventional treatments, there remains a high rate of mortality and disability. The production of B cells and autoantibodies plays a crucial role in the pathogenesis of IIM. Targeting B cells has emerged as an effective therapeutic strategy for IIM. This review aims to summarize the current state of B cell-targeted therapies for IIM, providing clinicians with potential treatment options.</p>","PeriodicalId":10423,"journal":{"name":"Clinical Reviews in Allergy & Immunology","volume":"68 1","pages":"40"},"PeriodicalIF":8.4000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985644/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Reviews in Allergy & Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12016-025-09047-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Idiopathic inflammatory myopathy (IIM) is a group of heterogeneous diseases that can affect multiple systems. Currently, it is classified into different subtypes based on myositis-specific antibodies and muscle tissue pathology. These subtypes vary in treatment response and clinical prognosis, with poor treatment outcomes observed in cases of rapidly progressive interstitial lung disease and severe muscle involvement. Despite conventional treatments, there remains a high rate of mortality and disability. The production of B cells and autoantibodies plays a crucial role in the pathogenesis of IIM. Targeting B cells has emerged as an effective therapeutic strategy for IIM. This review aims to summarize the current state of B cell-targeted therapies for IIM, providing clinicians with potential treatment options.
期刊介绍：
Clinical Reviews in Allergy & Immunology is a scholarly journal that focuses on the advancement of clinical management in allergic and immunologic diseases. The journal publishes both scholarly reviews and experimental papers that address the current state of managing these diseases, placing new data into perspective. Each issue of the journal is dedicated to a specific theme of critical importance to allergists and immunologists, aiming to provide a comprehensive understanding of the subject matter for a wide readership.
The journal is particularly helpful in explaining how novel data impacts clinical management, along with advancements such as standardized protocols for allergy skin testing and challenge procedures, as well as improved understanding of cell biology. Ultimately, the journal aims to contribute to the improvement of care and management for patients with immune-mediated diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
